The researchers also noted that some newly approved monoclonal antibody treatments (aducanumab, lecanemab, and donanemab) unintentionally increased Aβ42 levels in cerebrospinal fluid, which ...

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...

Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

Prompted by the aducanumab controversy and inconclusive ... the “results of the lecanemab and donanemab trials highlight the complexity of Alzheimer disease itself.” The drugs’ ability ...

Like Aduhelm (aducanumab) lecanemab – also known as BAN2401 ... said it will seek accelerated FDA approval of its candidate donanemab later this year, based on the results of the phase ...

Eli Lilly has reported the results of its much-anticipated phase 3 trial of amyloid-targeting Alzheimer’s disease therapy donanemab ... the FDA for their Leqembi (lecanemab) amyloid drug ...

Lecanemab and donanemab received the green light from regulators last year but the benefits were deemed "too small to justify the costs" to the health service. Re:Cognition Health, based on Harley ...